Viewing Study NCT01523392



Ignite Creation Date: 2024-05-06 @ 12:14 AM
Last Modification Date: 2024-10-26 @ 10:46 AM
Study NCT ID: NCT01523392
Status: COMPLETED
Last Update Posted: 2014-10-08
First Post: 2012-01-30

Brief Title: A Pharmacodynamic Study With Ticagrelor in African American Patients
Sponsor: AstraZeneca
Organization: AstraZeneca

Study Overview

Official Title: A Randomized Open-Label Multiple Dose Crossover Multiple Center Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in African American Patients With Stable Coronary Artery Disease
Status: COMPLETED
Status Verified Date: 2014-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease
Detailed Description: A Randomized Open-Label Multiple Dose Crossover Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None